India would have a plant- derived drug on Dengue fever, soon

Mosquito

New Delhi: India’s largest Pharmaceutical Company- Sun Pharma has reportedly, signed an agreement with the International Centre for Genetic Engineering and Biotechnology- ICGEB, yesterday, on Wednesday, 4th May for turning a plant extract into a potential drug for dengue fever.

Dengue fever is being a dangerous decease is annually afflicting at least ten thousands of people and kills about two hundred of the people in the country (India).

Now, this drug company- Sun Pharma may also be the first among the others which has taken advantage of a new regulatory regime in India for encouraging the plant- derived drugs.

The said company as has accepted partnership with the International Centre for Genetic Engineering and Biotechnology- ICGEB, which is the biggest entity has been working on dengue drugs and vaccine for nearly two decades, which is really not the smaller period’s dedication. Moreover, the said entity recently reported the potency of a plant extract- Cissmpelos pariera, which is also known as abuta or laghupatha, for treating the said decease.

It was also seen in year 2015 in the month of November, that the India based Drug Controller General- DCGI (Drug Controller General of India) found clarifying the procedure for testing the potential new drugs which is deriving from the sources which are plant- based. The said DCGI is the Indian authority which is vetting the applications by the Drug developers for testing the new drugs.

Also, the Manufacturers of the Botanical Formulations found not knowing the issue as to whether they need to approach the DCGI or the Ministry of Ayurveda, Unani, Siddhi and Homepathy for the approval of the said drug.

Moreover, as per the Senior official- Mohammed Aslam, in the Department of Biotechnology, he said “there is now a third route since from November.” This Department had partially funded the said dengue drug research of ICGEB. Moreover, as per the said senior officer from department, now with such third route, the “plant- based extracts to be recognised as valid drugs that can be clinically tested,” easily.

Moreover, the officials from the Indian pharma major- Sun Pharma had not confirmed as to what is the route which the company would adopt for testing the said new drug.

FacebookTwitterGoogle+Pinterest

Related posts

Leave a Comment